AMIGO2表达作为宫癌中复发的预测因子,具有中等风险
Yuki Iida1,2, Mitsuhiko Osaki1,3, Shinya Sato2
1Division of Experimental Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan.
Molecular and clinical oncology
|June 16, 2023
概括
安福特林诱导的基因和开放式读取框架2 (AMIGO2) 表达预测宫癌患者的复发. 高AMIGO2水平表明预后较差,并可能指导辅助治疗决策.
科学领域:
- 在瘤学瘤学.
- 分子病理学分子病理学
- 癌症生物标志物 癌症生物标志物
背景情况:
- 再发性子宫癌的治疗选择有限,通常被认为是无法治愈的.
- 安福特林诱导基因和开放式读取框架2 (AMIGO2) 是结肠直肠和胃癌的已知预后因素.
- 在宫癌中AMIGO2的预后作用仍然未被探索.
研究的目的:
- 调查AMIGO2表达在原发性宫癌中的预后意义.
- 确定AMIGO2表达是否可以预测疾病复发和生存结果.
- 评估AMIGO2作为指导术后辅助治疗的潜在生物标志物.
主要方法:
- 在2005年至2016年期间接受治疗的101名原发性宫癌患者的回顾性分析.
- 免疫组织化学分析以评估瘤样本中的AMIGO2表达水平.
- 对AMIGO2表达的临床特征,无病生存期 (DFS) 和总生存期 (OS) 的检查.
主要成果:
- 具有高AMIGO2表达的患者表现出明显较短的5年DFS和OS (P<0.001).
- 在多变量分析中,AMIGO2被确定为DFS的独立预后因素 (P=0.0012).
- 高AMIGO2表达与复发率增加,淋巴结转移和不良病理特征相关.
结论:
- AMIGO2表达作为宫癌复发的潜在预测标记.
- AMIGO2水平可能有助于识别可能受益于术后辅助治疗的中等风险患者.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
03:18Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K
01:12Relative Risk
238
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
238
01:09Odds Ratio
186
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
186
01:20Comparing the Survival Analysis of Two or More Groups
228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K